Since the world wide spreading of SARS-COV2 2,406,745 suspected cases with 165,257 death ones have been recorded. COVID-19 is a highly contagious disease that spread via direct exposure to the droplets generated when an infected person cough or sneeze or touching surfaces that are contaminated with those droplets and then toughing the nose, eyes, mouth or any mucous membrane. The deleterious impact of COVID-19 on all life sectors and without the availability of specific treatment or protective vaccine, researchers started the adoption of repurposing principle to help with the management and containment of the virus. As we are running out of time, the discovery and development of new selective anti-COVID19 drugs is not a practical option; leaving us with the enrollment of already available drugs in this crisis. Many drugs are currently under clinical trials suggesting to decrease the mortality of infected patients using the theory of "cytokine storm", hyper inflammatory status as an example have shown that “oxidant storm” instead of cytokine storm is the primary pathogenesis cascade for causing mortality in the late stages of COVID-19. In this review article, we repurpose the well-known antibiotic Rolitetracycline as adjunctive management of COVID-19 suspected or infected patients based on the documented non antibiotic activities of tetracycline and hiring the docking technique.